First Trial Results: Ebola Vaccine Safe And Generates Immune Response
The first trial results of Ebola vaccine at Oxford University suggest the vaccine has an acceptable safety profile and is able to generate an immune response.
“The Ebola vaccine was well tolerated. Its safety profile is pretty much as we had hoped,” said professor Adrian Hill of the Jenner Institute at Oxford University who led the trial.
The results suggest that the vaccine is suitable for further testing in West Africa during the current outbreak. The Ebola vaccine is being co-developed by the US National Institutes of Health (NIH) and pharmaceutical firm GlaxoSmithKline (GSK) against the Zaire strain of Ebola, which is the one circulating in West Africa.
The first doses for use in large scale trials in West Africa have been delivered to Liberia by GSK.
The initial findings were published in the New England Journal of Medicine (NEJM).